1. Home
  2. NRSN vs BCG Comparison

NRSN vs BCG Comparison

Compare NRSN & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • BCG
  • Stock Information
  • Founded
  • NRSN 2017
  • BCG 2016
  • Country
  • NRSN Israel
  • BCG United States
  • Employees
  • NRSN N/A
  • BCG N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • BCG
  • Sector
  • NRSN Health Care
  • BCG
  • Exchange
  • NRSN Nasdaq
  • BCG Nasdaq
  • Market Cap
  • NRSN 29.8M
  • BCG 29.6M
  • IPO Year
  • NRSN 2021
  • BCG N/A
  • Fundamental
  • Price
  • NRSN $0.98
  • BCG $1.92
  • Analyst Decision
  • NRSN Buy
  • BCG
  • Analyst Count
  • NRSN 2
  • BCG 0
  • Target Price
  • NRSN $14.00
  • BCG N/A
  • AVG Volume (30 Days)
  • NRSN 202.0K
  • BCG 1.4M
  • Earning Date
  • NRSN 12-17-2025
  • BCG 11-13-2025
  • Dividend Yield
  • NRSN N/A
  • BCG N/A
  • EPS Growth
  • NRSN N/A
  • BCG N/A
  • EPS
  • NRSN N/A
  • BCG N/A
  • Revenue
  • NRSN N/A
  • BCG $173,961,000.00
  • Revenue This Year
  • NRSN N/A
  • BCG N/A
  • Revenue Next Year
  • NRSN N/A
  • BCG N/A
  • P/E Ratio
  • NRSN N/A
  • BCG N/A
  • Revenue Growth
  • NRSN N/A
  • BCG 7.45
  • 52 Week Low
  • NRSN $0.80
  • BCG $1.36
  • 52 Week High
  • NRSN $2.60
  • BCG $6.00
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 37.32
  • BCG 58.67
  • Support Level
  • NRSN $0.89
  • BCG $1.41
  • Resistance Level
  • NRSN $0.97
  • BCG $1.53
  • Average True Range (ATR)
  • NRSN 0.07
  • BCG 0.16
  • MACD
  • NRSN -0.01
  • BCG 0.01
  • Stochastic Oscillator
  • NRSN 26.22
  • BCG 63.22

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About BCG Binah Capital Group Inc. Common Stock

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

Share on Social Networks: